2seventy Bio (TSVT) said late Monday that it has agreed to be acquired by Bristol Myers Squibb (BMY) for a price of $5 per share in an all-cash deal valuing the company at about $286 million.
The price represents an 88% premium over the March 7 closing price of $2.66 per share, the multiple myeloma-focused biotech company said.
2seventy bio said its board has unanimously recommended the deal to shareholders, some of which already agreed to tender their shares in support of the acquisition.
The transaction is expected to close in Q2, after which 2seventy bio's shares will no longer be listed for trading on Nasdaq, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。